Scarica l'app Stockscreener
5.09
3.05%
-0.16
Dopo l'orario di chiusura:
5.24
0.15
+2.95%
Replimune Group Inc Borsa (REPL) Ultime notizie
Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025Contact Levi & Korsinsky - TradingView
Shareholders who lost money on Replimune Group, Inc. - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Altimmune, Inc. (ALT) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - GlobeNewswire Inc.
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Replimune (REPL) Faces Securities Class Action Following - GlobeNewswire
Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 - ACCESS Newswire
REPL Stock News: Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Replimune Group, Inc. Class Action Lawsuit - Morningstar
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors of Class - GlobeNewswire
Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection of Melanoma Drug - GlobeNewswire Inc.
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
Class Action Filed Against Replimune Group, Inc. (REPL)September 22, 2025 Deadline to JoinContact The Gross Law Firm - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd - Morningstar
Zurcher Kantonalbank Zurich Cantonalbank Boosts Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Investors in Replimune Group, Inc. (REPL): Protect Your RightsContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Replimune Group, Inc. (REPL) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of September 22, 2025 Deadline - ACCESS Newswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm - Morningstar
Key resistance and support levels for Replimune Group Inc.Downside Risk Evaluation and Stock Analysis - Newser
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - MarketScreener
Visualizing Replimune Group Inc. stock with heatmapsEntry Timing with Downside Risk Analysis - Newser
Securities Lawsuit Alert: Replimune Group, Inc. (REPL) InvestorsContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Shareholders of Replimune Group, Inc. Should Contact Levi & - GlobeNewswire
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - PR Newswire
Replimune Group Reports Increased Losses Amid Rising R&D Costs - TipRanks
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Stockhouse
Replimune Group, Inc. Sued for Securities Law Violations - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, - GlobeNewswire
Replimune Group Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Replimune Group (REPL) Reports Wider-than-Expected Quarterly Los - GuruFocus
Replimune Group: The Prospects For FDA Approval After Rejection (REPL) - Seeking Alpha
Shareholders that lost money on Replimune Group, Inc.(REPL) should contact The Gross Law Firm about pending Class ActionREPL - Barchart.com
Replimune Reports Fiscal First Quarter 2026 Financial Results an - GuruFocus
Biotech Replimune's Q1 net loss widens, cash balance drops - MarketScreener
Replimune Group, Inc. SEC 10-Q Report - TradingView
Replimune's Melanoma Drug Hits FDA Roadblock: Q1 Losses Widen to $86.7M as Clinical Trials Advance - Stock Titan
Replimune Group (REPL) Expected to Announce Earnings on Thursday - Defense World
Securities Fraud Class Action Filed Against Replimune Group, Inc. (REPL)Levi & Korsinsky Reminds Investors of September 22, 2025 - ACCESS Newswire
REPL DEADLINE: Replimune Group Investors Should Contact - GlobeNewswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Replimune - GlobeNewswire
REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Newsfile
The researchers who designed Replimune's melanoma drug study offer a rare, detailed protest of the FDA's CRL - Endpoints News
Replimune Group, Inc. Stockholders With Large Losses Should Contact Robbins LLP For Information About Leading The REPL Class Action Lawsuit - ACCESS Newswire
Securities Lawsuit Alert: Replimune Group, Inc. (REPL)Contact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Why Is Replimune Stock Trading Lower On Monday? - Benzinga
Replimune Shares Slide as FDA Dispute Over Cancer Drug Approval Comes to Light - MSN
Replimune’s Turmoil: What Comes Next? - StocksToTrade
REPL Stock Drops: A Closer Look - timothysykes.com
Replimune stock plunges after FDA cancer drug rejection details emerge By Investing.com - Investing.com Nigeria
Replimune stock plunges after FDA cancer drug rejection details emerge - Investing.com
REPL LAWSUIT ALERT: The Gross Law Firm Notifies Replimune Group, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PR Newswire
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):